Smith Barney Citigroup 2005 Healthcare Conference (Washington, DC)
Wednesday, March 30, 2005
Lehman Brothers Eighth Annual Global Healthcare Conference
(Miami, FL)
Friday, April 1, 2005
CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference
(New York, NY)
Monday, April 4, 2005
NEW YORK, March 29, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will be presenting an overview of the Company, including recent progress and upcoming milestones, at the following healthcare investor conferences:
-- Smith Barney Citigroup 2005 Healthcare Conference (Washington, DC)
Wednesday, March 30, 2005
4:50 p.m. Eastern Time
Mayflower Hotel (East Room)
A live audio webcast of Mr. Weiss' presentation will be available at http://www.veracast.com/webcasts/sbcitigroup/hc05/44215138.cfm and will be accessible on demand beginning approximately 1 hour after the conclusion of the live presentation.
-- Lehman Brothers Eighth Annual Global Healthcare Conference
(Miami, FL)
Friday, April 1, 2005
10:15 a.m. Eastern Time
Loews Miami Beach Hotel (Americana Salon 2)
A live audio webcast of Mr. Weiss' presentation will be available at http://customer.talkpoint.com/LEHM002/033005a_cs/default.asp?entity=Keryx and will be accessible on demand beginning approximately 1 hour after the conclusion of the live presentation.
-- CIBC Annual Biotechnology and Specialty Pharmaceuticals
Conference (New York City)
Monday, April 4, 2005
11:30 a.m. Eastern Time
Millennium Broadway Hotel (Room 3.04)
A live audio webcast of Mr. Weiss' presentation will be available at http://www.veracast.com/webcasts/cibcwm/biotech05/49107338.cfm and will be accessible on demand beginning approximately 1 hour after the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound for the treatment of diabetic nephropathy, which is in a Phase II/III clinical program. Additionally, Keryx is developing clinical-stage oncology compounds including KRX-0401, a novel, first-in-class, oral AKT inhibitor in Phase II clinical trials. Keryx also has an active in- licensing and acquisition program designed to identify and acquire clinical- stage drug candidates. Keryx Biopharmaceuticals is headquartered in New York City.